UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

Amy Jones, MD, discusses future research efforts in pancreatic cancer.

Syed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.

Syed Kazmi, MD, highlights the go-to regimens for patients with mCRC.

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.

Amit G. Singal, MD, MS, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma.

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

Sawsan Rashdan, MD, discusses the current treatment paradigm of patients with resectable and metastatic EGFR-mutant NSCLC.

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

Syed Rizvi, MD, discusses the limitations of doxorubicin, bleomycin, vinblastine, and dacarbazine in Hodgkin lymphoma.

Ankit Kansagra, MD, discusses updates with CAR T-cell therapy in multiple myeloma.

Larry Anderson, MD, PhD, discusses the phase II GRIFFIN trial examining the addition of daratumumab (Darzalex) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) in patients with multiple myeloma.

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.

Syed Rizvi, MD, discusses research efforts exploring brentuximab vedotin combinations in patients with Hodgkin lymphoma.

Amit Singal, MD, MS, discussess optimal models for multidisciplinary care in hepatocellular carcinoma in light of the practice-changing IMbrave150 trial.

Prapti Patel, MD, discusses data from the MEDALIST trial on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndromes.

Farrukh Awan, MD, discusses the rationale for combining BTK inhibitors with CD20-directed monoclonal antibodies in CLL, sequencing challenges, and remaining questions in the chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.